Advances in male hormonal contraception
暂无分享,去创建一个
[1] A. Matsumoto,et al. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. , 2002, Journal of andrology.
[2] N. Moeloek,et al. Achieving azoospermia by injections of testosterone undecanoate only or combined with depot medroxyprogesterone acetate in Indonesian men , 2001 .
[3] J. Greer,et al. Pharmacological and endocrine characterization of A‐198401, an orally active GnRH antagonist, in intact and castrate male rat models , 2001 .
[4] E. Nieschlag,et al. Potential of norethisterone enanthate for male contraception: pharmacokinetics and suppression of pituitary and gonadal function. , 2001, Clinical endocrinology.
[5] K. Herbst,et al. Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. , 2000, Fertility and sterility.
[6] H. Baker,et al. Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception. , 2000, Contraception.
[7] A. von Eckardstein,et al. Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo‐controlled feasability study for male contraception , 2000, Clinical endocrinology.
[8] K. Sundaram,et al. 7alpha-methyl-19-nortestosterone (MENT): the optimal androgen for male contraception and replacement therapy. , 2000, International journal of andrology.
[9] P. Ho,et al. Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. , 2000, Human reproduction.
[10] M. Steiner. Contraceptive effectiveness: what should the counseling message be? , 1999, JAMA.
[11] D. Baird,et al. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. , 1999, The Journal of clinical endocrinology and metabolism.
[12] W. Bremner,et al. A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. , 1999, The Journal of clinical endocrinology and metabolism.
[13] A. Negro-Vilar. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. , 1999, The Journal of clinical endocrinology and metabolism.
[14] J. Suvisaari,et al. Gonadotrophin and testosterone suppression by 7alpha-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men. , 1999, Human reproduction.
[15] A. Matsumoto,et al. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. , 1999, Journal of andrology.
[16] E. Nieschlag,et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. , 1999, European journal of endocrinology.
[17] A. von Eckardstein,et al. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. , 1999, The Journal of clinical endocrinology and metabolism.
[18] L. Hamann,et al. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071). , 1999, Journal of medicinal chemistry.
[19] A. Matsumoto,et al. The therapeutic potential of testosterone patches. , 1998, Expert opinion on investigational drugs.
[20] D. Cummings,et al. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. , 1998, The Journal of clinical endocrinology and metabolism.
[21] W. Bremner,et al. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. , 1998, Journal of andrology.
[22] S. Sasaki,et al. Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. , 1998, Journal of medicinal chemistry.
[23] R. Swerdloff,et al. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. , 1998, The Journal of clinical endocrinology and metabolism.
[24] W. Bremner,et al. Low dose of cyproterone acetate and testosterone enanthate for contraception in men. , 1998, Human reproduction.
[25] J. Edwards,et al. Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. , 1998, Journal of medicinal chemistry.
[26] W. Bremner,et al. An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. , 1997, Fertility and sterility.
[27] A. Pollack,et al. Results of a pilot study of the time to azoospermia after vasectomy in Mexico City. , 1997, Contraception.
[28] J. Suvisaari,et al. Pharmacokinetics and pharmacodynamics of 7alpha-methyl-19-nortestosterone after intramuscular administration in healthy men. , 1997, Human reproduction.
[29] David Handelsman,et al. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. , 1996, The Journal of clinical endocrinology and metabolism.
[30] Contraceptive efficacy of testosterone‐induced azoospermia and oligozoospermia in normal men , 1996, Fertility and sterility.
[31] W. Bremner,et al. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. , 1996, The Journal of clinical endocrinology and metabolism.
[32] P. McDonough,et al. Correction to "World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 1996;65:821-9." , 1996 .
[33] R. Anderson,et al. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. , 1996, The Journal of clinical endocrinology and metabolism.
[34] K. Herbst,et al. Testosterone administration to normal men decreases truncal and total body fat , 1996 .
[35] A. Matsumoto,et al. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. , 1996, The Journal of clinical endocrinology and metabolism.
[36] I. Feuerstein,et al. Very low high-density lipoproteins without coronary atherosclerosis , 1993, The Lancet.
[37] E. Seeman,et al. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception. , 1993, The Journal of clinical endocrinology and metabolism.
[38] A. Matsumoto,et al. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. , 1993, The Journal of clinical endocrinology and metabolism.
[39] E. Wallace,et al. Prostate-specific antigen and prostate gland size in men receiving exogenous testosterone for male contraception. , 1993, International journal of andrology.
[40] David Handelsman,et al. Suppression of human spermatogenesis by testosterone implants. , 1992, The Journal of clinical endocrinology and metabolism.
[41] S. Bhasin,et al. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. , 1992, The Journal of clinical endocrinology and metabolism.
[42] J. Lindner,et al. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. , 1991, The Journal of clinical endocrinology and metabolism.
[43] M. Dean. London Perspective Manicures and Chablis but no extra NHS cash , 1990, The Lancet.
[44] David Handelsman,et al. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. , 1990, The Journal of clinical endocrinology and metabolism.
[45] J. Geelen,et al. The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen. , 1975, Acta endocrinologica.
[46] Victor C. Strasburger,et al. Contraception , 1924, The Indian Medical Gazette.
[47] E. Nieschlag,et al. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. , 2001, The Journal of clinical endocrinology and metabolism.
[48] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[49] Y. Gui,et al. Inhibitine effects of sino-implant plus testosterone undecanoate (TU) on spermatogenesis in Chinese men. , 1999, Reproduction and contraception.
[50] R. Balasubramanian,et al. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. , 1999, The Journal of clinical endocrinology and metabolism.
[51] M. Pandian,et al. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. , 1992, The Journal of clinical endocrinology and metabolism.